

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 December 2009 (10.12.2009)

PCT

(10) International Publication Number
WO 2009/148730 A1

(51) International Patent Classification:
A61K 31/20 (2006.01) *A23D 7/01* (2006.01)

(21) International Application Number:
PCT/US2009/042275

(22) International Filing Date:
30 April 2009 (30.04.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/058,243 3 June 2008 (03.06.2008) US

(71) Applicant (for all designated States except US): **MEAD JOHNSON NUTRITION COMPANY** [US/US]; 2400 W. Lloyd Expressway, Evansville, IN 47721-0001 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **PETSCHOW, Bryon, W.** [US/US]; 11 Hickory Hill Drive, Ewing, NJ 08618 (US).

(74) Agent: **SHOUSE, Emily, A.**; Waddey & Patterson, Roundabout Plaza, 1600 Division Street, Suite 500, Nashville, TN 37203 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: METHOD FOR INHIBITING THE GROWTH OF BACTERIA

(57) Abstract: The present invention is directed to a method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent.



WO 2009/148730 A1

DESCRIPTION

METHOD FOR INHIBITING THE GROWTH OF BACTERIA

BACKGROUND OF THE INVENTION

[0001] The present invention relates generally to a method for inhibiting the growth of pathogenic bacteria in an infant formula.

DISCLOSURE OF THE INVENTION

[0002] Briefly, therefore, the present invention is directed to a novel method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent.

[0003] In another aspect, the present invention is a method for inhibiting the growth of *Enterobacter sakazakii* (*E. sakazakii*) in an infant formula comprising supplementing the infant formula with at least one diglyceride.

[0004] In yet another aspect, the present invention is a method for inhibiting the growth of *H. pylori* in an infant formula comprising supplementing the infant formula with at least one diglyceride.

BEST MODE FOR CARRYING OUT THE INVENTION

[0005] Reference now will be made in detail to the embodiments of the invention, one or more examples of which are set forth below. Each example is provided by way of explanation of the invention, not limitation of the invention. In fact, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be used on another embodiment to yield a still further embodiment.

[0006] Thus, it is intended that the present invention cover such modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features and aspects of the present invention are disclosed in or are obvious from the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not intended as limiting the broader aspects of the present invention.

[0007] The term “infant” means a human that is less than about 18 months of age.

[0008] The term “child” means a human that is between about 18 months and 12 years of age. In some embodiments, a child is between the ages of about 18 months and 6 years. In other embodiments, a child is between the ages of about 7 and 12 years.


[0009] As used herein, the term “infant formula” means a composition that satisfies the nutrient requirements of an infant by being a substitute for human milk.

[00010] Diglycerides, also referred to as diacylglycerols, are glycerides consisting of two fatty acid chains covalently bonded to a glycerol molecule through ester linkages. Diglycerides can have many different combinations of fatty acids attached at the C-1 and C-2 positions.

[00011] Diglycerides are natural components of various edible oils that are found in low amounts in all vegetable oils. They are used in small quantities in some foods as emulsifiers, and are often found in bakery products, beverages, ice cream, chewing gum, shortening, whipped toppings, mayonnaise, margarine, and confections. In recent years, diglycerides have received interest from researchers in food science, biochemistry, and nutrition because of the wide spectrum of benefits provided by diglycerides, including delaying the progression of renal failure and promoting weight loss.

[00012] Diglycerides are important intermediates in the biosynthesis of triglycerides and phospholipids, and play a fundamental role in cellular signaling. They act as signaling molecules by binding directly to many different proteins and further regulate cell growth and apoptosis. Diglycerides can activate cellular mechanisms directly via protein activation or indirectly via the liberation of fatty acids, which may be metabolized in agonist molecules.

[00013] The structure of diglyceride is shown below:



[00014] As noted, the present invention is directed to a method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with at least one diglyceride antimicrobial agent. The pathogenic bacterial growth inhibited through the method of the invention may, in an embodiment, be any pathogenic bacteria known in the art, including any member of the group *Enterobacteriaceae*. In another embodiment, the pathogenic bacteria which experience growth inhibition as a result of the invention may be *Vibrio cholerae*, *Escherichia coli*, *Shigella sonnei*, *Salmonella typhi*, *E. sakazakii*, or *Helicobacter pylori* (*H. pylori*). In a particular embodiment, the pathogenic bacterium is *E. sakazakii*. In another embodiment, the pathogenic bacterium inhibited by the method of the present invention is *H. pylori*.

[00015] In an embodiment of the invention, the infant formula contains an amount of diglyceride that is between about 0.25 and 10 g per L of formula. In another embodiment of the invention, the infant formula contains an amount of diglyceride that is between about 2.5 and 5 g per L of formula. In a particular embodiment of the invention, the infant formula contains an amount of diglyceride that is about 2.5 g per L of formula.

[00016] As used in the present invention, the source of diglyceride can be any source known in the art such as plant material, animal material, synthetic material,

and the like. Commercial sources of diglyceride may be either animal (typically, cow- or hog-derived) or vegetable (derived primarily from soy bean and canola oil).

[00017] In an embodiment of the invention, the diglyceride inhibits the growth of either or both of gram-positive and gram-negative bacteria.

[00018] In another embodiment, the diglyceride may be effective in inhibiting bacterial growth in nutritional compositions, children's nutritional products, or human milk fortifiers or supplements. Thus, the method of the invention may be useful for inhibiting the growth of pathogenic bacteria in products for a human infant, child, or adult.

[00019] The infant formula of the invention can be a term infant formula or a preterm infant formula. The infant formula of the invention can further be a liquid (ready-to-use or concentrated) or powder. If the infant formula of the invention is a powder, it may be reconstituted to liquid form with water prior to use.

[00020] In the invention, an infant formula is supplemented with at least one diglyceride. In a particular embodiment, the infant formula is supplemented with at least two diglycerides. In another embodiment, the infant formula is supplemented with at least three diglycerides.

[00021] In an embodiment, the infant formula of the invention may be nutritionally complete and contain suitable types and amounts of lipids, carbohydrates, proteins, vitamins and minerals. The amount of lipid or fat typically can vary from about 3 to about 7 g per 100 kcal. The amount of protein typically can vary from about 1 to about 5 g per 100 kcal. The amount of carbohydrate typically can vary from about 8 to about 12 g per 100 kcal. Protein sources can be any used in the art, *e.g.*, nonfat milk, whey protein, casein, soy protein, hydrolyzed protein, amino acids, and the like. Carbohydrate sources can be any used in the art, *e.g.*, lactose, glucose, corn syrup solids, maltodextrins, sucrose, starch, rice syrup solids, and the like. Lipid sources can be any used in the art, *e.g.*, vegetable oils such as palm oil, canola oil, corn oil, soybean oil, palmolein, coconut oil, medium chain triglyceride oil, high oleic sunflower oil, high oleic safflower oil, and the like.

[00022] Conveniently, commercially available infant formula can be used. For example, Enfamil®, Enfamil® Premature Formula, Enfamil® with Iron, Enfamil® LIPIL®, Lactofree®, Nutramigen®, Pregestimil®, and ProSobee® infant formulas (available from Mead Johnson & Company, Evansville, IN, U.S.A.) may be

supplemented with suitable levels of diglyceride and used in practice of the method of the invention.

[00023] In some embodiments of the invention, the infant formula may be supplemented with at least one other antimicrobial agent. This other antimicrobial agent may be any antimicrobial agent known in the art, assuming it is compatible with the other components of the infant formula. These other antimicrobial agents may be fatty alcohols, monoglycerides, and/or free fatty acids and their corresponding esters, including monoglycerol esters.

[00024] In some embodiments of the invention, the infant formula containing at least one diglyceride may be supplemented with additional components. These additional components may include probiotics, prebiotics, or long chain polyunsaturated fatty acids (LCPUFAs).

[00025] The term “probiotic” means a microorganism that exerts beneficial effects on the health of the host. Any probiotic known in the art may be used, provided it is suitable for supplementing an infant formula containing diglyceride. For example, the probiotic may be chosen from the group consisting of *Lactobacillus* and *Bifidobacterium*. Alternatively, the probiotic can be *Lactobacillus rhamnosus* GG.

[00026] The term “prebiotic”, as used herein, means a non-digestible food ingredient that stimulates the growth and/or activity of probiotics. In this embodiment, any prebiotic known in the art may be used, provided it is suitable for supplementing an infant formula containing diglyceride. In a particular embodiment, the prebiotic can be selected from the group consisting of fructo-oligosaccharide, gluco-oligosaccharide, galacto-oligosaccharide, inulin, isomalto-oligosaccharide, polydextrose, xylo-oligosaccharide, lactulose, and combinations thereof.

[00027] While not wishing to be bound to this or any theory, it is believed that a method for inhibiting the growth of pathogenic bacteria in an infant formula supplemented with prebiotics and diglycerides may provide a synergistic effect. More specifically, it is believed that the prebiotic may alter the composition of the gut flora to provide a greater number of beneficial bacteria and fewer pathogenic bacteria, further contributing to the antimicrobial effect of the diglyceride in the present invention.

[00028] Furthermore, it is believed that a method for inhibiting the growth of pathogenic bacteria in an infant formula supplemented with probiotics and diglycerides may provide a synergistic effect. More specifically, it is believed that the probiotic may alter the composition of the gut flora to provide a greater number of beneficial bacteria and fewer pathogenic bacteria, further contributing to the antimicrobial effect of the diglyceride in the present invention.

[00029] In yet another embodiment of the invention, the infant formula may be supplemented with LCPUFAs and at least one diglyceride. In this embodiment, the LCPUFAs may include docosahexaenoic acid (DHA), arachidonic acid (ARA), and/or eicosapentaenoic acid (EPA).

[00030] If the infant formula is supplemented with LCPUFAs as part of the present invention, the weight ratio of ARA:DHA may be from about 1:3 to about 9:1. In one embodiment of the present invention, this ratio is from about 1:2 to about 4:1. In yet another embodiment, the ratio is from about 2:3 to about 2:1. In one particular embodiment the ratio is about 2:1. In another particular embodiment of the invention, the ratio is about 1:1.5. In other embodiments, the ratio is about 1:1.3. In still other embodiments, the ratio is about 1:1.9. In a particular embodiment, the ratio is about 1.5:1. In a further embodiment, the ratio is about 1.47:1.

[00031] If the infant formula is supplemented with DHA as part of the present invention, the level of DHA may be between about 0.0% and 1.00% of fatty acids, by weight. In other embodiments, the level of DHA may be about 0.32% by weight. In some embodiments, the level of DHA may be about 0.33% by weight. In another embodiment, the level of DHA may be about 0.64% by weight. In another embodiment, the level of DHA may be about 0.67% by weight. In yet another embodiment, the level of DHA may be about 0.96% by weight. In a further embodiment, the level of DHA may be about 1.00% by weight.

[00032] If the infant formula is supplemented with ARA as part of the present invention, the level of ARA may be between 0.0% and 0.67% of fatty acids, by weight. In another embodiment, the level of ARA may be about 0.67% by weight. In another embodiment, the level of ARA may be about 0.5% by weight. In yet another embodiment, the level of DHA may be between about 0.47% and 0.48% by weight.

[00033] If the infant formula is supplemented with DHA as part of the present invention, the amount of DHA may be from about 2 mg per 100 kilocalories (kcal) to about 100 mg per 100 kcal. In another embodiment, the amount of DHA may be from about 5 mg per 100 kcal to about 75 mg per 100 kcal. In yet another embodiment, the amount of DHA may be from about 15 mg per 100 kcal to about 60 mg per 100 kcal.

[00034] If the infant formula is supplemented with ARA as part of the present invention, the amount of ARA may be from about 4 mg per 100 kilocalories (kcal) to about 100 mg per 100 kcal. In another embodiment, the amount of ARA may be from about 10 mg per 100 kcal to about 67 mg per 100 kcal. In yet another embodiment, the amount of ARA may be from about 20 mg per 100 kcal to about 50 mg per 100 kcal. In a particular embodiment, the amount of ARA may be from about 25 mg per 100 kcal to about 40 mg per 100 kcal. In one embodiment, the amount of ARA is about 30 mg per 100 kcal.

[00035] If the infant formula is supplemented with DHA as part of the present invention, the effective amount of DHA may be from about 3 mg per kg of body weight per day to about 150 mg per kg of body weight per day. In one embodiment of the invention, the amount is from about 6 mg per kg of body weight per day to about 100 mg per kg of body weight per day. In another embodiment the amount is from about 15 mg per kg of body weight per day to about 60 mg per kg of body weight per day.

[00036] If the infant formula is supplemented with ARA as part of the present invention, the effective amount of ARA may be from about 5 mg per kg of body weight per day to about 150 mg per kg of body weight per day. In one embodiment of this invention, the amount varies from about 10 mg per kg of body weight per day to about 120 mg per kg of body weight per day. In another embodiment, the amount varies from about 15 mg per kg of body weight per day to about 90 mg per kg of body weight per day. In yet another embodiment, the amount varies from about 20 mg per kg of body weight per day to about 60 mg per kg of body weight per day.

[00037] If the infant formula of the invention is supplemented with oils containing LCPUFAs, it may be accomplished using standard techniques known in the art. For example, an equivalent amount of an oil which is normally present in a composition, such as high oleic sunflower oil, may be replaced with the LCPUFAs.

[00038] If utilized, the source of the LCPUFAs can be any source known in the art such as marine oil, fish oil, single cell oil, egg yolk lipid, brain lipid, and the like. The LCPUFAs can be in natural form or refined form.

[00039] In an embodiment, the invention comprises a method of inhibiting the growth of pathogenic bacteria in a nutritional composition, the method comprising adding at least one diglyceride to the nutritional composition. In a particular embodiment, the invention comprises a method of inhibiting the growth of *E. sakazakii* in a powdered infant formula, the method comprising adding at least one diglyceride to the infant formula. In yet another embodiment, the invention comprises a method of inhibiting the growth of *H. pylori* in a powdered infant formula, the method comprising adding at least one diglyceride to the infant formula.

[00040] All references cited in this specification, including without limitation, all papers, publications, patents, patent applications, presentations, texts, reports, manuscripts, brochures, books, internet postings, journal articles, periodicals, and the like, are hereby incorporated by reference into this specification in their entireties. The discussion of the references herein is intended merely to summarize the assertions made by their authors and no admission is made that any reference constitutes prior art. Applicants reserve the right to challenge the accuracy and pertinence of the cited references.

[00041] These and other modifications and variations to the present invention may be practiced by those of ordinary skill in the art, without departing from the spirit and scope of the present invention, which is more particularly set forth in the appended claims. In addition, it should be understood that aspects of the various embodiments may be interchanged in whole or in part. Furthermore, those of ordinary skill in the art will appreciate that the foregoing description is by way of example only, and is not intended to limit the invention so further described in such appended claims. Therefore, the spirit and scope of the appended claims should not be limited to the description of the preferred versions contained therein.

CLAIMS

What is claimed is:

1. A method for inhibiting the growth of pathogenic bacteria in an infant formula comprising supplementing the infant formula with from about 0.25 to about 10 g per L of formula of at least one diglyceride antimicrobial agent.
2. The method of claim 1 wherein the infant formula is supplemented with an amount of diglyceride that is between about 1.25 and 5 g per L of formula.
3. The method of claim 1 wherein the infant formula is supplemented with an amount of diglyceride that is about 2.5 g per L of formula.
4. The method of claim 1 additionally comprising supplementing the infant formula with at least one LCPUFA.
5. The method of claim 5 wherein the LCPUFA is selected from the group consisting of DHA, ARA, EPA, and combinations thereof.
6. The method of claim 1 additionally comprising supplementing the infant formula with at least one probiotic.
7. The method of claim 1 additionally comprising supplementing the infant formula with at least one prebiotic.
8. The method of claim 1 wherein the infant formula is further supplemented with at least one additional antimicrobial agent.
9. The method of claim 8 wherein the at least one additional antimicrobial agent is selected from the group consisting of a fatty alcohol, a monoglyceride, a free fatty acid, the corresponding ester of a free fatty acid, and combinations thereof.
10. The method of claim 1 wherein the pathogenic bacteria inhibited by the diglyceride is selected from the group consisting of gram-positive bacteria, gram-negative bacteria, and combinations thereof.
11. The method of claim 1 wherein the infant formula is a powdered formula.
12. The method of claim 1 wherein the infant formula is in liquid form.
13. The method of claim 1 wherein the pathogenic bacteria comprises *E. sakazakii*.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 09/42275

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/20 ; A23D 7/01 (2009.01)

USPC - 514/558, 426/601

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC - 426/601; 514/558

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC - 426/531, 426/601, 426/665, 426/801; 514/553, 514/557, 514/558

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST (PGPB, USPT, USOC, EPAB, JPAB); Google

Diglyceride, diacylglycerol, antimicrobial, antibacterial, LCPUFA, long chain polyunsaturated fatty acids, docosahexaenoic acid, DHA, arachidonic acid, ARA, eicosapentaenoic acid, EPA, probiotic, prebiotic, powdered, liquid, Enterobacter, and sakazakii

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 5,908,862 A (Wai Lee et al.) 01 June 1999 (01.06.1999); col 1 ln 64 to col 2 ln 1; col 2 ln 41-42; col 5 ln 16-22 and 59-60; col 6 ln 62-64; and col 13 ln 7-9	1-3 and 8-13 4-7
Y	US 2004/0101596 A1 (Ndife et al.) 27 May 2004 (27.05.2004), para [0043]	4-5
Y	US 2007/0254062 A1 (Singhal et al.) 01 November 2007 (01.11.2007), para [0056]	6-7

☐ Further documents are listed in the continuation of Box C.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

01 June 2009 (01.06.2009)

Date of mailing of the international search report

19 JUN 2009

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents

P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300

PCT OSP: 571-272-7774